Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 17/20 | 1.00 |
| ▸ | ACACA | Q13085 | 10/20 | 0.74 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1547851 | 1.00 | ACACB (1.00) | ACACBACACAMTNR1AMTNR1B | |
| SCHEMBL1547288 | 1.00 | ACACB (1.00) | ACACBACACAMTNR1AMTNR1B | |
| SCHEMBL1547656 | 0.95 | ACACB (1.00) | ACACBACACAMTNR1AMTNR1B | |
| SCHEMBL1547635 | 0.91 | ACACB (0.91) | ACACBACACA | |
| SCHEMBL1547380 | 0.90 | ACACB (0.82) | ACACBACACAMTNR1AMTNR1B | |
| SCHEMBL1547657 | 0.88 | ACACB (0.79) | ACACBACACA | |
| Trifluoroacetic Acid SCHEMBL1547775 | 0.88 | ACACB (0.77) | ACACBACACAMTNR1AMTNR1B | |
| SCHEMBL2166309 | 0.86 | ACACB (0.80) | ACACBACACAMTNR1AMTNR1B | |
| SCHEMBL1547655 | 0.86 | ACACB (0.76) | ACACBACACA | |
| SCHEMBL18090590 | 0.86 | ACACB (1.00) | ACACBACACAMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3670496-A2 | ACC2 INHIBITORS | Shionogi&Co., Ltd. (JP) | 2020-06-24 | — | — | EP | disclosed |
| US-20190144396-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2019-05-16 | — | — | US | disclosed |
| US-10233156-B2 | 9-membered fused ring derivative | SHIONOGI & CO., LTD. (JP) | 2019-03-19 | — | — | US | disclosed |
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20160257641-A1 | NOVEL ALKYLENE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2016-09-08 | — | — | US | disclosed |
| US-20160257641-A1 | NOVEL ALKYLENE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2016-09-08 | — | — | US | disclosed |
| EP-3059225-A1 | NOVEL ALKYLENE DERIVATIVE | Shionogi & Co., Ltd. (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-8470841-B2 | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof | SANOFI (FR) | 2013-06-25 | — | — | US | disclosed |
| US-8470841-B2 | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof | SANOFI (FR) | 2013-06-25 | — | — | US | disclosed |
| US-8470841-B2 | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof | SANOFI (FR) | 2013-06-25 | — | — | US | disclosed |
| US-20110183998-A1 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | disclosed |
| US-20110183998-A1 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | disclosed |
| US-20110183998-A1 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | disclosed |
| WO-2010003624-A2 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | ACSS2, AGTR2, ACSL3 | ACACB 7/4885ACACA 12/4885MTNR1A 3285/4885 |
| US-20110183998-A1 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | CS, CYP11B1, GPR119 | ACACB 1290/4885ACACA 1283/4885MTNR1A 560/4885 |
| US-20190144396-A1 | 9-MEMBERED FUSED RING DERIVATIVE | ACSS2, AGTR2, ACSL3 | ACACB 7/4885ACACA 12/4885MTNR1A 3285/4885 |
| US-10233156-B2 | 9-membered fused ring derivative | AGTR2, ACSS2, ACSL3 | ACACB 5/4885ACACA 10/4885MTNR1A 3215/4885 |
| US-20160257641-A1 | NOVEL ALKYLENE DERIVATIVES | ACSS2, ACACB, ADCY2 | ACACB 2/4885ACACA 18/4885MTNR1A 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.